skip to main content
Idioma:

Impact of parenteral opioid shortage on opioid prescriptions among patients seen by the palliative care team of a comprehensive cancer center

Haider, Ali ; Qian, Yu ; Lu, Zhanni ; Naqvi, Syed Mussadiq Ali Akbar ; Zhuang, Amy ; Reddy, Akhila Sunkepally ; Dalal, Shalini ; Arthur, Joseph Anthony ; Tanco, Kimberson Cochien ; Dev, Rony ; Williams, Janet L. ; Wu, Jimin ; Liu, Diane D. ; Bruera, Eduardo

Journal of clinical oncology, 2018, Vol.36 (34_suppl), p.201-201 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Impact of parenteral opioid shortage on opioid prescriptions among patients seen by the palliative care team of a comprehensive cancer center
  • Autor: Haider, Ali ; Qian, Yu ; Lu, Zhanni ; Naqvi, Syed Mussadiq Ali Akbar ; Zhuang, Amy ; Reddy, Akhila Sunkepally ; Dalal, Shalini ; Arthur, Joseph Anthony ; Tanco, Kimberson Cochien ; Dev, Rony ; Williams, Janet L. ; Wu, Jimin ; Liu, Diane D. ; Bruera, Eduardo
  • É parte de: Journal of clinical oncology, 2018, Vol.36 (34_suppl), p.201-201
  • Descrição: Abstract only 201 Background: Recent parenteral opioid shortage (POS) has the potential to impact cancer pain management in hospitalized patients. This study aims to compare changes in the opioid prescriptions by the inpatient palliative care (PC) team before and after the institution first reported the POS. Methods: We reviewed and compared the electronic health records of 386 consecutive eligible consultations seen by the inpatient PC team equally in one month before and after the announcement of POS on February 8, 2018. The eligibility criteria include (1) cancer diagnosis, (2) ≥18 years of age, (3) taking opioid medication at the time of consultation, and (4) having at least two consecutive visits with the PC team. Patient demographics, cancer type, opioid type, route, and dose defined as the morphine equivalent daily dose were assessed. Results: POS was associated with less use of parenteral opioids (patient controlled analgesia, and intravenous breakthrough) and more use of non-parenteral opioids (extended release, transdermal, and oral breakthrough) by the referring oncology teams, and PC team (P≤.001) (Table 1). At first PC follow-up, significantly less proportion of patients achieved better pain control after POS [119/193 (62%) versus 144/193 (75%) (P=.006)] However, at second PC follow-up, the proportion of pain improvement was similar in both cohorts. Conclusions: There is a significant change in opioid routes associated with POS. POS was associated with worse analgesia. More research is needed to better understand the impact of POS on cancer pain management.[Table: see text]
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  2 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.